866-997-4948(US-Canada Toll Free)

Firmagon (Prostate Cancer) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Dec 2012

Category :

Cancer

No. of Pages : 47 Pages

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Firmagon (Prostate Cancer) - Forecast and Market Analysis to 2022. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. 

For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

Ferring’s Firmagon is a synthetic peptide that targets the LHRH receptor. It is differentiated from its competitors in that it acts as an LHRH receptor antagonist rather than as an agonist (that is, an LHRH analog). Firmagon is prescribed for patients with advanced prostate cancer and is administered monthly as a subcutaneous injection. The binding of Firmagon to the LHRH receptor rapidly results in decreased testosterone production without the testosterone flare that is characteristic of treatment with LHRH receptor agonists.

Scope
  • Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Firmagon including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Firmagon for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia 
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Firmagon performance 
  • Obtain sales forecast for Firmagon from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)
Table of Contents

1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 6

2 Introduction 7
2.1 Catalyst 7
2.2 Related Reports 8
2.3 Upcoming Related Reports 9

3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 10
3.1.3 Prognosis 11
3.1.4 Quality of Life 12
3.2 Symptoms 13

4 Disease Management 14
4.1 Diagnosis and Referral Overview 14
4.2 Treatment Overview 16
4.2.1 Conservative Management Strategies 20
4.2.2 Localized Treatments 21
4.2.3 Hormone Therapy 22
4.2.4 Drug Therapies 24

5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27

6 Firmagon (degarelix) 30
6.1 Overview 30
6.2 Efficacy 31
6.3 Safety 32
6.4 SWOT Analysis 32
6.5 Forecast 33

7 Appendix 35
7.1 Bibliography 35
7.2 Abbreviations 39
7.3 Methodology 40
7.4 Forecasting Methodology 40
7.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 41
7.4.2 Percent Drug-treated Patients 41
7.4.3 Percent Hormone Therapy-Treated Patients 41
7.4.4 General Pricing Assumptions 42
7.4.5 Individual Drug Assumptions 44
7.4.6 Generic Erosion 44
7.5 Physicians and Specialists Included in This Study 44
7.6 Survey of Prescribing Physicians 45
7.7 About the Authors 46
7.7.1 Authors 46
7.7.2 Global Head of Healthcare 46
7.8 About GlobalData 47
7.9 Contact Us 47
7.10 Disclaimer 47

List of Table


Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 12
Table 2: Global Variations in Recommendations on Routine PSA Screening 14
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 17
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 19
Table 5: Leading Treatments for Prostate Cancer, 2012 29
Table 6: Product Profile - Firmagon 31
Table 7: Firmagon SWOT Analysis, 2012 33
Table 8: Global Sales Forecasts ($m) for Firmagon, 2012-2022 34
Table 9: Physicians Surveyed, By Country 45

List of Chart


Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *